“CemiplimAb-Rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s756. Accessed May 19, 2026. https://skin.dermsquared.com/skin/article/view/4093.